Dr. Lan Coffman presents updated Phase III MIRASOL trial results comparing overall survival and safety outcomes of mirvetuximab soravtansine (MIRV) versus investigator’s choice chemotherapy in patients with platinum-resistant ovarian cancer and high folate receptor-alpha expression.

Dr. Alexander Drilon presents an update from the Phase 1/2 ALKOVE-1 study, investigating the efficacy and safety of NVL-655, a selective ALK inhibitor, in patients with ALK-positive solid tumors, highlighting durable responses in heavily pre-treated populations, including those with compound ALK resistance mutations and central nervous system involvement.

Dr. Martin Dietrich presents updated efficacy and safety data from the Phase 2 PHAROS study, evaluating encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic non-small cell lung cancer, showing sustained clinical activity and a consistent safety profile after extended follow-up.

Dr. Pankit Vachhani presents key data from the CYTO-PV and MAJIC-PV studies, evaluating the efficacy of ruxolitinib versus best available therapy in patients with polycythemia vera, focusing on clinical outcomes such as cardiovascular risk reduction, hematocrit management, and long-term molecular responses.

Dr. Lorenza Rimassa presents a five-year overall survival analysis from the Phase 3 HIMALAYA study, demonstrating sustained survival benefits of the STRIDE regimen versus sorafenib in patients with unresectable hepatocellular carcinoma (uHCC).

Dr. Saad Usmani discusses the results of the Phase 3 CEPHEUS study, which evaluated the combination of daratumumab with bortezomib/lenalidomide/dexamethasone (D-VRd) in transplant-ineligible or transplant-deferred patients with newly diagnosed multiple myeloma, highlighting its impact on progression-free survival and minimal residual disease negativity.

Dr. Rafael Fonseca presents the primary results of the phase 3 AURIGA study, which demonstrates the significant improvement in MRD-negative conversion and progression-free survival with subcutaneous daratumumab plus lenalidomide versus lenalidomide alone as maintenance therapy in newly diagnosed multiple myeloma post-transplant, shared at the 2024 International Myeloma Society Annual Meeting.

The ARROS-1 Phase 1/2 study investigates the safety, tolerability, and efficacy of zidesamtinib (NVL-520), a ROS1-selective, brain-penetrant tyrosine kinase inhibitor, in heavily pre-treated patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) and other solid tumors, showing promising durable responses in both systemic and intracranial disease.

Maurice Pérol, MD, presents a pooled analysis of two pivotal Phase 2 trials assessing the efficacy and safety of taletrectinib in patients with advanced ROS1+ non-small cell lung cancer.

Dr. Xiuning Le highlights real-world data on therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations, emphasizing the need for improved treatments, at ESMO Congress 2024.

Everett E. Vokes, MD, FASCO, from University of Chicago Medicine, presents interim results from a phase 3 trial comparing petosemtamab plus pembrolizumab versus pembrolizumab monotherapy for first-line treatment of recurrent/metastatic PD-L1-positive head and neck squamous cell carcinoma at the 2024 ESMO Annual Meeting.

Jacob Sands, MD, presents promising early-phase trial results for obrixtamig, a novel DLL3-targeting T-cell engager, in patients with large cell neuroendocrine carcinoma of the lung (LCNEC-L), shared at ESMO Congress 2024.

Scott Plotkin, MD, reviews data from a phase II study on brigatinib, a multi tyrosine kinase inhibitor, across various tumor types in patients with NF2-related schwannomatosis.

David Miller, MD, reviews a plenary presentation (originally presented at the ASCO 2024 Annual Meeting by Vikky Makker, MD) on the long-term follow-up of the ENGOT-EN5/GOG-3055/SIENDO trial, focusing on selinexor maintenance for patients with TP53 wild-type advanced or recurrent endometrial cancer.

VICTORIA (NCT05192642), is an exact-matching study comparing the outcomes of patients with TRK fusion cancer treated with larotrectinib in 3 clinical trials (NCT02122913, NCT02576431, NCT02637687) to patients treated with non-TRK inhibitor therapies in the real-world (RW) setting.

Misako Nagasaka, MD, PhD, discusses the use of trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer and recent NCCN guideline updates based on the DESTINY-Lung-01 HER2 overexpression cohort data.

BGB-11417-101 is a global phase 1/1b study evaluating sonrotoclax as monotherapy, or in combination ± zanubrutinib, and ± obinutuzumab in patients with B-cell malignancies. (NCT04277637)

A Phase 1b study (NCT03013998) to determine the safety and recommended dose of Revumenib combined with Aza/Ven in patients with newly diagnosed AML ≥ 60 years old with NPM1mut or KMT2Ar and who are not candidates or do not wish to pursue intensive induction therapy.

The aim of this study is to describe the demographic, clinical, and treatment characteristics of patients with LRMDS who were managed by physicians at Florida Cancer Specialists & Research Institute (FCS) and treated with ESAs, and to determine the proportion of LR-MDS patients who experience ESA failure and describe treatment patterns following ESA failure.

Preliminary results for treatment with zanubrutinib + venetoclax in patients with high-risk TN CLL/SLL with del(17p) and/or TP53 mutation showed Promising efficacy in a high-risk population with deep and durable responses according to data from arm D of the phase 3 SEQUOIA trial (NCT03336333).

BGB-16673-101 (NCT05006716) is a phase 1 study of a bruton tyrosine kinase degrader (BGB-16673) in patients with relapsed or refractory CLL/SLL.

DREAMM-8 (NCT04484623) is an ongoing, randomized, open-label, phase 3 study evaluating BPd vs PVd in patients with RRMM previously treated with ≥1 line of therapy including lenalidomide.

An economic analysis of Zanubrutinib versus Acalabrutinib and associated QoL benefits in AE management in patients with B-cell malignancies.

The study assessed the comparative efficacy of zanubrutinib vs acalabrutinib in patients with R/R MCL, in the absence of head-to-head clinical trials, using population-adjusted indirect treatment comparison via simulated treatment comparison approach. Data source for the efficacy of zanubrutinib was informed by the pooled individual patient-level data from 2 clinical trials: BGB-3111-206 (NCT03206970) and BGB-3111-AU-003 (NCT02343120). The efficacy of acalabrutinib was informed by the published aggregated data of the ACE-LY-004 trial (NCT02213926).

A phase 3, randomized, double-blind, placebo-controlled study to determine if prior TAS-102 and/or regorafenib treatment status and sequence affect the efficacy and safety of fruquintinib in patients with mCRC. This study used data from both FRESCO (NCT02314819) and FRESCO-2 (NCT04322539).

DREAMM-7 (NCT04246047) is a global, randomized, open-label, phase III head-to-head trial evaluating the efficacy and safety of BVd triplet vs SoC triplet, DVd, in patients (pts) with RRMM with ≥1 prior line of therapy.

Zanidatamab is a HER2-targeted bispecific antibody that binds to two non-overlapping HER2 domains and crosslinks neighboring HER2 proteins. In the primary analysis of the phase 2b HERIZON-BTC-01 trial (NCT04466891), after a median follow-up of 12.4 months, zanidatamab showed encouraging antitumor activity with rapid and durable responses and a manageable safety profile in patients with previously treated HER2+ BTC.

Tropion-Lung05 (NCT04484142) is a phase 2, multicenter, single-arm, open-label study evaluating Dato-DXd in patients with advanced/metastatic NSCLC with actionable genomic alterations who have progressed on or after targeted therapy and platinum-based CT.

Dr. Aditya Bardia presents the findings of DESTINY-Breast06 (NCT04494425) in chemotherapy naive patients with HER2-low and HER2-ultra low metastatic breast cancer demonstrating progression-free survival of trastuzumab deruxtecan compared to chemotherapy treatment of physician’s choice.

IMROZ (NCT03319667) is the first global Phase 3 study of an anti-CD38 mAb in combination with VRd in patients with transplant-ineligible NDMM.

Dr. Natasha Leighl presents the primary results of the phase 3, randomized controlled PALOMA-3 (NCT05388669) trial assessing the overall survival and non-inferiority of subcutaneous amivantamab compared to intravenous amivantamab, in combination with lazertinib, in patients with refractory EGFR-mutated, advanced non-small cell lung cancer.

The LAURA study (NCT03521154) evaluates the efficacy and safety of Osimertinib as a maintenance therapy following chemoradiotherapy in patients with unresectable stage III EGFR-mutated non-small cell lung cancer.

This is a final overall survival analysis on the phase 3 CARES-310 study (NCT03764293), a randomized, open-label, international phase 3 trial comparing camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC).

This is safety and efficacy update on the MANIFEST-2 trial (NCT02158858), a global, randomized, double-blind, active-control, phase 3 study using pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve patients with myelofibrosis.

A secondary investigation stemming from the Phase 3 MARIPOSA study, this analysis stratifies outcomes of utilizing amivantamab plus lazertinib compared to osimertinib in the treatment of first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) by biomarkers and disease characteristics indicative of high-risk disease.

Jorge Cortes, MD, discusses 4-year outcomes with ponatinib in patients with chronic myeloid leukemia harboring a T315I mutation.

A 3 year survival update on the RELATIVITY-047 trial (NCT03470922), a global, randomized, double-blind phase 2/3 study comparing nivolumab plus relatlimab vs nivolumab in previously untreated metastatic or unresectable stage III or IV melanoma.

Dr. Martin Reck presents the five year update of CheckMate 9LA (NCT03215706) and exploratory analysis of efficacy in patients who discontinued treatment due to treatment related adverse events in patients with metastatic non-small lung cancer.

CROWN (NCT03052608) is a phase 3 clinical trial evaluating progression free survival with the use of loratinib in patients with advanced ALK+ NSCLC.

COMBI-AD (NCT01682083) evaluated dabrafenib plus trametinib for patients with BRAF-mutated AJCC-stage III melanoma, and here the final results for RFS, distant-metastasis-free survival and overall survival are presented.

PIVOTAL (NCT02938299) is an open label, randomized, multicenter, phase 3 trial evaluating Daromun as a neoadjuvant intralesional therapy for resectable, locally advanced Stage III melanoma.

This is an evaluation of the results of a network meta-analysis covering the comparative efficacy of bruton tyrosine kinase Inhibitors in relapse/refractory chronic lymphocytic leukemia.

Dr. Jérôme Fayette presents the findings of a phase 2 study (NCT03526835) assessing the overall response rate of petosemtamab in combination with pembrolizumab compared to pembrolizumab monotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma.

Dr. Nader Sanai presents the findings of a phase 0/1 trigger trial (NCT06072586) that evaluates the CNS penetration of BDTX-1535 in patients with recurrent high-grade gliomas and EGFR mutations.

Christine Lovly, MD, PhD, shares data on BDTX-1535, a “masterkey” EGFR inhibitor targeting classical, non-classical, and the C797S resistance mutation in patients with EGFR mutant non-small cell lung cancer (NSCLC), from a presentation at AACR 2024.

Dr. Constantine Tam provides an overview of the current and emerging treatment landscape for chronic lymphocytic leukemia (CLL), with a focus on Bruton's tyrosine kinase (BTK) inhibitors like ibrutinib and the next generation of BTK inhibitors under development.

William Harris, MD, presents the study design and rationale for HCRN GI15-225, an open-label, single-arm multicenter, pilot study exploring whether using immunotherapy drugs in combination with locoregional therapies for patients with non-metastatic HCC is safe and beneficial, using pembrolizumab every 3 weeks starting 1 week before initial Y90 radioembolization.

Brian Slomovitz, MD, MS, FACOG, presents the study design, rationale, and primary endpoints of ENGOT-EN20/GOG-3083/XPORT-EC-042, which will be evaluating the efficacy of selinexor compared with placebo as maintenance therapy in patients with advanced or recurrent TP53wt endometrial cancer.

Thomas J. Herzog, MD, examines the PAOLA-1 trial results, focusing on the primary endpoint of progression-free survival (PFS) and key secondary endpoint of overall survival for olaparib in combination with bevacizumab for the treatment of advanced ovarian cancer. He discusses the 5-year overall survival data in relation to the PFS data and reviews the safety profile of the combination therapy with over 5 years of median follow-up. Dr. Herzog also considers the impact of these data on clinical decision-making and patient counseling from the perspective of a practicing gynecologic oncologist.

Jacob Sands, MD, shares updated data from the phase 3 TROPION-Lung01 trial of datopotamab deruxtecan versus docetaxel in non-squamous non-small cell lung cancer recently presented at the 2024 European Lung Cancer Congress (ELCC).

Sara Tolaney, MD, MPH, presents an exploratory pooled analysis of efficacy and safety data of trastuzumab deruxtecan vs comparator in patients with HER2-positive metastatic breast cancer and brain metastases from DESTINY-Breast01, -02, and -03.

Matthew Powell, MD, presents findings from a second interim analysis of part 1 from the ENGOT-EN6-NSGO/GOG-3031/RUBY trial investigating the combination of dostarlimab-gxly plus carboplatin/paclitaxel compared with placebo/chemotherapy in patients with primary advanced or recurrent endometrial cancer.

Domenica Lorusso, MD, PhD, presents the final overall survival data from the randomized open -label phase 2 trial of relacorilant, a selective glucocorticoid receptor modulator in combination with nab-paclitaxel versus nab-paclitaxel alone in patients with recurrent platinum resistant ovarian cancer.

Zachariah DeFilipp, MD, presents data from AGAVE-201, a phase 2, open-label, randomized, multicenter study evaluating axatilimab at 3 dose levels in patients with recurrent/refractory chronic graft-versus-host disease (GVHD).

Enrique Grande, MD, PhD, Msc, presents the results of a multi-cohort basket phase II trial, CABATEN/GETNE-T1914, evaluating cabozantinib plus atezolizumab in patients with locally advanced/metastatic adrenocortical carcinoma.

Joshua Richter, MD, FACP, presents recent National Comprehensive Cancer Network (NCCN) guideline updates in the treatment of multiple myeloma.

Mazyar Shadman, MD, MPH, presents data from a matching adjusted indirect comparison (MAIC) of the efficacy of zanubrutinib versus acalabrutinib in relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) based on data from the Phase 3 ALPINE and Phase 3 ASCEND trials.

Joshua K. Sabari, MD, reviews data from the 5-year overall survival update from the POSEIDON study investigating durvalumab, tremelimumab, and chemotherapy in first-line metastatic non–small cell lung cancer.

Michael Wang, MD, presents the primary analysis results from the multinational, randomized, double-blind, phase 3 SYMPATICO study comparing ibrutinib plus venetoclax vs ibrutinib plus placebo in patients with relapsed/refractory mantle cell lymphoma (R/R MCL).

Erika Hamilton, MD, presents data from the phase 3 HER2CLIMB-02 study investigating tucatinib and trastuzumab emtansine in patients with previously treated HER2+ metastatic breast cancer.

In his discussion of the CHECKMATE 8HW trial, Dr. Tanios Bekaii-Saab examined the efficacy of chemotherapy versus nivolumab plus ipilimumab as the initial treatment for metastatic colorectal cancer with high microsatellite instability and deficient mismatch repair.

Yelena Y. Janjigian, MD, presents 4-year follow-up data from the CheckMate 649 study investigating frontline nivolumab plus chemotherapy in patients with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma.

Dr. Sonpavde discusses the efficacy and safety findings from this randomized, open-label trial enrolling patients with advanced or metastatic urothelial carcinoma who had not received prior systemic chemotherapy.

Nizar Tannir, MD, FACP, presents extended follow-up data assessing the combination of nivolumab and ipilimumab compared with sunitinib in the frontline setting of patients with advanced renal cell carcinoma (RCC).

Komal L. Jhaveri, MD, FACP, presents key data on the addition of inavolisib to palbociclib and fulvestrant vs palbociclib and fulvestrant alone in select patients with PIK3CA-mutated, hormone receptor–positive, HER2-negative, locally advanced, or metastatic breast cancer.

Hetty Carraway, MD, presents the updated results, with over two years of follow-up, in treatment-naïve patients with BPDCN to assess tagraxofusp safety and efficacy in the real-world setting.

Sara A. Hurvitz, MD, presents data from the phase 3 HER2CLIMB-02 study investigating tucatinib and trastuzumab emtansine in patients with previously treated HER2+ metastatic breast cancer.

Lorenzo Falchi, MD, discusses the ongoing EPCORE FL-1 phase 3 trial investigating epcoritamab-rituximab-lenalidomide vs rituximab-lenalidomide in patients with relapsed or refractory follicular lymphoma.

Dr. Usmani, MD, MBA, FACP provides insights into Selinexor's safety profile in Relapsed/Refractory Multiple Myeloma (R/R MM), comparing it with other treatments and delve into the ongoing challenges and unmet needs in R/R MM patient care.

An expert explores factors influencing the selection of treatment regimens in relapsed, triple class refractory multiple myeloma (MM) patients, with a focus on prophylactic measures for managing adverse events associated with novel agents like Selinexor, bispecific, and CAR-T therapies.

Amer Zeidan, MBBS, MHS, presents data from the IMerge phase 3 study on the efficacy of imetelstat in achieving red blood cell transfusion independence across different risk subgroups in patients with lower-risk myelodysplastic syndromes relapsed/refractory to erythropoiesis-stimulating agents.

Elizabeth Budde, MD, PhD, presents data from the 3-year follow-up from a pivotal phase II study investigating mosunetuzumab monotherapy in patients with relapsed and/or refractory follicular lymphoma after ≥2 prior therapies.

Stephen Chan, MD, presents real-world data from a systemic review of treatment patterns in the United States of patients with hepatocellular carcinoma from 2020 to 2022.

Elizabeth Budde, MD, PhD, presents data from on mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma.

Francesca Gay, MD, PhD, presents results from the phase III randomized IsKia trial investigating isatuximab-carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in patients with newly diagnosed multiple myeloma.

Constantine S. Tam, MD, MBBS, presents the biomarker subgroup analysis from the phase 3 SEQUOIA study investigating zanubrutinib in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma without del(17p).

Jennifer R. Brown, MD, PhD, presents data from the extended follow-up of the ALPINE study investigating zanubrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

Claire Roddie, MD, PhD, presents data from the pooled analysis of the ongoing FELIX phase Ib/II study investigating obecabtagene autoleucel in patients with relapsed/refractory adult B-cell acute lymphoblastic leukemia.

Guillermo Garcia-Manero, MD, presents data from the COMMANDS trial investigating luspatercept in erythropoiesis-stimulating agent-naive patients with transfusion-dependent lower-risk myelodysplastic syndromes.

Raajit K. Rampal, MD, PhD, presents data from the MANIFEST-2 study investigating pelabresib in combination with ruxolitinib in Janus kinase inhibitor treatment–naïve patients with myelofibrosis.

Catherine C. Coombs, MD, presents data investigating venetoclax-based therapy after Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia.

Saad Usmani, MD, MBA, FACP, discusses the updates of XPO1 inhibitors in relapsed/refractory multiple myeloma patients.

Aditya Bardia, MD, presents key data from biomarker and subgroup analyses of the EMERALD trial.

Alexey Danilov, MD, PhD, reviews data from the TRANSCEND NHL 001 study investigating lisocabtagene maraleucel in patients with relapsed/refractory mantle cell lymphoma.

SPONSORED CONTENT: Morie Gertz, MD, reviews data on the use of birtamimab plus standard-of-care anti-plasma cell chemotherapy in patients with light-chain amyloidosis, which was investigated in the phase 3 randomized, placebo-controlled VITAL trial.

Mark A. Socinski, MD, reviews data from the PAPILLON study presented at ESMO 2023 on amivantamab plus chemotherapy vs chemotherapy in the first line for patients with EGFR exon 20 insertion–mutated advanced non–small cell lung cancer.

Hope Rugo, MD reviews key data from the CAPItello-291 phase 3 trial recently presented at the San Antonio Breast Cancer Symposium in December 2022.

Benjamin Solomon, MBBS, PhD, FRACP, presents key data from the ALINA study investigating alectinib versus chemotherapy as adjuvant therapy in patients with stage IB–IIIA anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC).

Grace Dy, MD, presents data from the CARMEN-LC04 study evaluating safety and anti-tumor activity of tusamitamab ravtansine combined with ramucirumab in high CEACAM5-expressing non-squamous cell (NSQ) NSCLC tumors.

Expert oncologist Alex Spira, MD, PhD, FACP, reviews primary results from the MARIPOSA study in advanced NSCLC following the ESMO 2023 annual meeting.

Brian Slomovitz, MD, provides a look at an upcoming Rapid Readout program looking at the results of a phase 3 study of tisotumab vedotin in patients with recurrent or metastatic cervical cancer.

Aaron Lisberg, MD, reviews data from the TROPION-Lung01 study investigating Dato-DXd in previously treated patients with advanced/metastatic NSCLC.

Terence Friedlander, MD, presents significant data from the EV-302/KEYNOTE-A39 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma.

Expert oncologist Benjamin Levy, MD, shares data from the LIBRETTO-431 trial comparing selpercatinib to chemotherapy plus pembrolizumab in RET fusion-positive NSCLC following ESMO 2023.

Martin Dietrich, MD, PhD, presents key data from the phase 3 MARIPOSA-2 study, which investigated amivantamab plus chemotherapy, with or without lazertinib, versus chemotherapy in patients with EGFR-mutated advanced NSCLC who experienced disease progression on osimertinib.

Shannon Westin, MD, reviews the results of the Phase III DUO-E/GOG-3041/ENGOT-EN10 trial in patients with newly diagnosed advanced or recurrent endometrial cancer.

Expert oncologist Aditya Bardia, MD, reflects on data from the TROPION-Breast01 trial of dato-DXd versus chemotherapy in metastatic HR+/HER2– breast cancer following ESMO 2023.

Expert oncologist Yasir Elamin, MD, shares data from the BRIGHTSTAR trial and considers how it may inform real-world use of brigatinib in patient with ALK-rearranged metastatic non–small cell lung cancer.

Expert oncologist Helena Yu, MD, reviews data from HERTHENA-Lung01 following the IASLC 2023 World Conference on Lung Cancer and considers how patritumab deruxtecan will fit into clinical practice.

Sandip P. Patel, MD, reviews data from the preliminary results of the EVOKE-02 study investigating sacituzumab govitecan plus pembrolizumab in first-line metastatic non–small cell lung cancer.

Sponsored Content: Neal Shore, MD, FACS reviews new data on the TITAN trial of apalutamide in patients with mCSPC.

Jason R. Westin, MD, MS, FACP, presents the overall survival analysis from ZUMA-7, a phase 3 study investigating axicabtagene ciloleucel (axi-cel) versus standard-of-care therapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).

Arvind Dasari, MD, MS, presents data from the FRESCO-2 clinical trial evaluating fruquintinib in patients with refractory metastatic colorectal cancer, and provides insights on the clinical implications of the results.

Whitney S. Graybill, MD, MS, presents data from an analysis of the phase 3 PRIMA trial that looked to identify baseline characteristics associated with long-term progression-free survival with niraparib in patients with advanced ovarian cancer.

Marcelo Negrao, MD, presents key data from the KRYSTAL-1 trial investigating adagrasib in patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC) and untreated central nervous system (CNS) metastases.

Jane Lowe Meisel, MD, presents data from a retrospective study investigating patient characteristics, treatment patterns, and clinical outcomes for tucatinib-based treatment in the real-world setting both overall and following fam-trastuzumab deruxtecan (T-DXd).

Alexey Danilov, MD, PhD, reviews data from the phase 2 TRANSCEND FL trial investigating lisocabtagene maraleucel and discusses the clinical implications of the results.

Marwan G. Fakih, MD, reviews data from the phase 3 randomized SUNLIGHT trial investigating trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer.

Dr. Christopher Flowers showcases a comprehensive and updated analysis of the ROSEWOOD study, evaluating the efficacy and safety of combining zanubrutinib with obinutuzumab versus obinutuzumab monotherapy.

Expert Amir Fathi, MD, reviews recent clinical data with ziftomenib in patients with relapsed/refractory acute myeloid leukemia.

Matthew Powell, MD, presents data from the blinded independent central review of the RUBY trial, which studied dostarlimab in patients with primary advanced or recurrent endometrial cancer.

Jason R. Westin, MD, MS, FACP, reviews the background and study design of ZUMA-23, the first Phase III, randomized controlled study to evaluate CAR T-cell therapy as a first-line regimen in patients with high-risk LBCL.

Alexey Danilov, MD, PhD, presents an analysis of data from the Phase 1 TRANSCEND CLL 004 study investigating lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL.

Paolo Ghia, MD, PhD, reviews data from the ELEVATE-RR trial investigating acalabrutinib versus ibrutinib for the treatment of relapsed/refractory chronic lymphocytic leukemia (R/R CLL).

Greg Roloff, MD, reviews data on the outcomes of patients with relapsed/refractory B-ALL who received treatment with brexucabtagene autoleucel.

Key opinion leader Mazyar Shadman, MD, MPH, reviews data from a clinical trial studying zanubrutinib in the context of ibrutinib- and/or acalabrutinib-intolerant CLL/SLL.

Expert Michael Atkins, MD, reviews data from the ongoing IGNYTE study utilizing RP1 in combination with nivolumab in relapsed/refractory melanoma.

Timothy Cloughesy, MD, reviews data from the phase 3 INDIGO trial investigating vorasidenib in patients with residual or recurrent grade 2 glioma with an IDH1 or IDH2 mutation.

Claire Harrison, MD, reviews the use of ruxolitinib in patients who are ineligible for hydroxycarbamide for the management of polycythemia vera (PV).

Guillermo Garcia-Manero, MD, reviews data from the COMMANDS trial comparing the efficacy and safety of luspatercept to epoetin alfa in patients with lower-risk myelodysplastic syndromes (MDS) who are dependent on blood transfusions and have not previously received erythropoiesis-stimulating agents (ESAs).

Expert Scott Tagawa, MD, MS, FASCO, FACP, reviews recent clinical trial data on UGT1A1- and Trop-2–guided treatment of metastatic urothelial carcinoma.

Expert Helen Ajufo, MD, reviews data from the PERSIST-2 overall survival analysis and its implications for the management of patients with myelofibrosis.

Expert hematologist-oncologist Grzegorz Nowakowski, MD, reviews data from the 5-year analysis of the L-MIND study combining tafasitamab with lenalidomide in relapsed/refractory diffuse large B-cell lymphoma.

Expert oncologist John Heymach, MD, PhD, reviews data from the phase 3 AEGEAN trial following updates presented at the 2023 AACR annual meeting.

Expert Elias Jabbour, MD, reviews clinical data from the PhALLCON study of ponatinib vs imatinib in patients with Ph+ acute lymphocytic leukemia and considers its clinical implications.

Jayesh Desai, MBBS, FRACP, shares data from a phase IB study investigating KRAS G12C inhibitor GDC-6036, or divarasib, in combination with cetuximab for the treatment of patients with colorectal cancer.

Alexander I. Spira, MD, PhD, shares new dose escalation data from the first-in-human Phase 1 KIN-2787 study of the pan-RAF inhibitor exarafenib in patients with BRAF-altered solid tumors or NRAS-mutant melanoma.

Mansoor R. Mirza, MD, reviews data from the phase 3 RUBY trial investigating dostarlimab in combination with carboplatin and paclitaxel for the treatment of primary advanced or recurrent endometrial cancer.

Expert Matthew D. Galsky, MD, shares his perspective on follow-up results from CheckMate 274, which analyzed adjuvant nivolumab in patients with high-risk muscle-invasive urothelial carcinoma.

Expert oncologist Matthew Smith, MD, PhD, reviews efficacy and safety data from the phase 3 ARASENS study combining darolutamide with ADT and docetaxel in patients with metastatic hormone-sensitive prostate cancer.

Amod Sarnaik, MD, reviews data from a study presented at The Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting on lifileucel tumor-infiltrating lymphocyte [TIL] monotherapy in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapy.

Yelena Y. Janjigian, MD, reviews the 3-year follow-up data from the CheckMate 649 trial investigating nivolumab plus chemotherapy as a first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma.

Expert hematologist-oncologist Thomas G. Martin, MD, shares data from the IKEMA subgroup analysis in patients with relapsed multiple myeloma treated with isatuximab, carfilzomib, and dexamethasone.

Pau Montesinos, MD discusses key updates from the global phase 3 AGILE study, as presented at the 2022 American Society of Hematology Annual Meeting, and speaks to the clinical implications of these data.

Do-Youn Oh, MD reviews the updated OS results of the phase 3 study, TOPAZ-1, evaluating the use of durvalumab plus GemCis versus placebo for patients with advanced biliary tract cancer (BTC).

Hope Rugo, MD discusses key data updates on the TROPiCS-02 study on sacituzumab govitecan in patients with endocrine-resistant, HR+/HER2- advanced breast cancer that were recently presented at the 2022 San Antonio Breast Cancer Symposium.

Dr Anthony Mato reviews the extended follow-up results from the phase 1/2 BRUIN Study that evaluated the use of pirtobrutinib in patients with lymphoma.

Dr Aaron Gerds provides insights and reviews updated data from the MOMENTUM study that evaluated the use of momelotinib in patients with myelofibrosis who previously received a JAK inhibitor.

Nicole Lamanna, MD, reviews the results of the phase 3 study evaluating the use of zanubrutinib versus ibrutinib for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Dr Aaron Gerds discusses the long term safety data of momelotinib, a JAK1/JAK2 inhibitor, in patients with myelofibrosis.

Sara A. Hurvitz, MD, reviews updated data comparing trastuzumab deruxtecan versus trastuzumab emtansine for the treatment of HER2+ metastatic breast cancer.

Dr Ajay Chari reviews the results from the MonumenTAL-1 trial which evaluates the use of talquetamab, a GPRC5D x CD3 bispecific antibody in patients with relapsed refractory multiple myeloma.

Virginia Kaklamani, MD reviews updated results and clinical implications of the phase 3 EMERALD trial evaluating elacestrant in patients with ER+/HER2- metastatic breast cancer presented at the 2022 San Antonio Breast Cancer Symposium.

Dr Uwe Platzbecker reviews data on imetelstat in patients with lower-risk myelodysplastic syndromes (MDS) that were recently presented at the 2022 American Society of Hematology (ASH) Annual Meeting.

Shaji Kumar, MD, reviews the results of the phase 3 study evaluating the use of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM).

Brian A Jonas, MD, reviews the results of the phase 1 study evaluating the use of uproleselan in combination with azacitidine and venetoclax in patients that are older or unfit for treatment naïve acute myeloid leukemia (AML).

Harry Erba, MD, PhD shares an update from the recent ASH 2022 Annual Meeting on a phase 1/2 trial of the menin-KMT2A (MLL) Inhibitor ziftomenib in patients with relapsed or refractory acute myeloid leukemia.

Dr Stephen Oh reviews the use of pacritinib in patients with myelofibrosis and the impact on anemia. Funding supported by CTI Biopharma. Content independently developed by OncLive.

Peter A. Kaufman, MD, reviews data in patients with HER2+ metastatic breast cancer treated with tucatinib-based therapy.

Tapan M. Kadia, MD evaluates the use of uproleselan, an E-selectin antagonist, in combination with LDAC and Cladribine in patients with treated secondary acute myeloid leukemia.

Dr Thomas Hutson reviews recently published data on patient outcomes and estimated healthcare costs associated with use of third-line cabazitaxel versus a second ARTA in patients with metastatic castration-resistant prostate cancer (CRPC).

Dr Leif Stenke reviews data on XS004 in patients with chronic myeloid leukemia (CML) that were recently presented at the 2022 American Society of Hematology (ASH) Annual Meeting.

Sponsored by BeiGene. Content developed independently by OncLive. Dr Tam reviews the risk of atrial fibrillation along with other cardiovascular events in patients who either receive ibrutinib or zanubrutinib for b-cell malignancies.

Dr Worden reviews and discusses real-world data of lenvatinib monotherapy in patients with radioiodine-refractory differentiated thyroid cancer.

Dr Cabanillas reviews updated data that was recently presented at the American Thyroid Association conference on the use of larotrectinib in patients with advanced TRK fusion positive thyroid cancer.

Dr Sara M Tolaney reviews data from the APHINITY trial regarding the pertuzumab plus trastuzumab and chemotherapy treatment regimen for patients with HER2+ breast cancer.

Dr Oh reviews data assessing the impact of pacritinib on anemia in patients from the PERSIST-2 trial. Funding supported by CTI BioPharma. Content independently developed by OncLive.

Dr. Hope Rugo reviews updates to data from the TROPiCS-02 trial that were recently presented at ESMO Congress 2022 and speaks to clinical implications of these data.

Dr Cairo reviews results from a real-world observational study comparing the incidence of tumor lysis syndrome (TLS)-associated fatalities between rasburicase monotherapy and allopurinol monotherapy.

Dr Hubbard reviews patient reported outcomes from the MOUNTAINEER trial, which evaluated the combination of tucatinib plus trastuzumab in patients with HER2-positive metastatic colorectal cancer.

Dr. El-Khoueiry evaluates the efficacy and safety of camrelizumab in combination with rivoceranib for the treatment of unresecetable hepatocellular carcinoma in the front-line setting.

Dr Finn reviews the results from the Leap-002 study which evaluates the use of lenvatinib with pembrolizumab in the front-line setting for patients with advanced hepatocellular carcinoma.

Dr Domenica Lorusso reviews data updates from KEYNOTE-775 that were recently presented at the European Society for Medical Oncology (ESMO) Congress 2022.

Dr. Tanios Bekaii-Saab discusses the results of a systematic review/meta-analysis intended to assess the impact of EGFR-targeted therapies on clinical outcomes in patients with HER2-positive metastatic colorectal cancer.

Dr Solange Peters reviews data from POSEIDON on combination durvalumab, tremelimumab, and chemotherapy in patients with metastatic non-small cell lung cancer (mNSCLC) that were recently presented at the 2022 World Conference on Lung Cancer.

Dr. Nicholas Short reviews updates to data on combination ponatinib and blinatumomab in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that were recently presented at the 2022 European Hematology Association (EHA) Congress.

Dr Tanios Bekaii-Saab reviews data from the MOUNTAINEER trial on combination tucatinib/trastuzumab in patients with HER2-positive metastatic colorectal cancer.

Dr Levy presents updated safety and efficacy results on larotrectinib in patients with TRK fusion-positive lung cancer.

Dr Benjamin Levy reviews long-term, pooled safety and efficacy data on larotrectinib in patients with TRK fusion-positive cancers.

Dr Nooka reviews the patient reported outcomes from the MajesTEC-1 trial in patients with relapsed/refractory multiple myeloma.

Dr. Pau Montesinos reviews the efficacy of ivosidenib and azacitidine in reducing transfusions and improving blood counts in patients with newly diagnosed acute myeloid leukemia.

Dr Elisabet Manasanch reviews updated data from the IKEMA study in patients with relapsed multiple myeloma.

Dr. Tycel Phillips reviews pivotal dose-expansion results from the EPCORE NHL-1 trial on epcoritamab in patients with relapsed or refractory large B-cell lymphoma (LBCL).

Dr Vinod Ravi talks about nab-SIROLIMUS and reviews the data from the AMPECT trial.

Dr. Kim reviews the RASER study and discusses how radiation segmentectomy could be a potential treatment option for patients with unresectable hepatocellular carcinoma.

Dr. Waguespack reviews efficacy and safety data for larotrectinib in patients with TRK fusion-positive thyroid carcinoma.

Dr. Pal analyzes and reviews the results from long term follow-up data on PFS from the TIVO-3 trial.

Expert urologist Benjamin Lowentritt, MD, reviews advanced prostate cancer data from the SPARTAN and TITAN studies comparing patient-reported outcomes to changes in PSA.

Dr. Natalie Callander reviews data from the DREAMM-5 study presented at ASH 2021, which assessed the safety and efficacy of belantamab mafodotin plus feladilimab in patients with relapsed/refractory multiple myeloma with disease resistance to at least 3 prior lines of therapy.

Dr. Tripathy reviews the safety and efficacy data from a phase 2 non-randomized study of tucatinib-trastuzumab-capecitabine regimen in patients with leptomeningeal metastasis.

Expert urologist Benjamin Lowentritt, MD, reviews trial data comparing PsA response achieved with apalutamide versus enzalutamide in patients with castration-sensitive prostate cancer.

Alan H. Bryce, MD, discusses the ARASENS trial, as presented at The American Society of Clinical Oncology Genitourinary Cancers Symposium in February 2022.

Sagar Lonial, MD, discusses the part 1 results of a study combining belantamab mafodotin with pomalidomide and dexamethasone when treating relapsed/refractory multiple myeloma, as presented by Suzanne Trudel, MD, at the American Society of Hematology 2021 Annual Meeting.

Expert perspective on the INSURE study, which pooled data from several trials to observe the real-world effectiveness of IRd in the setting of relapsed/refractory multiple myeloma.

Insight on the observational GALAXY study, which analyzed the relationship between circulating tumor DNA and clinical outcomes in the adjuvant management of colorectal cancer.

Expert hematologist/oncologist Paul Szabolcs, MD, reviews positive data from a clinical trial comparing hematopoietic stem cell transplantation and omidubicel with standard cord blood transplantation.

Michael Atkins, MD, shares data presented at the 2021 American Society of Clinical Oncology Plenary Series regarding results from the phase 3 ECOG-ACRIN EA6134 trial, DREAMseq, evaluating the use of up-front dual immunotherapy in patients with BRAF V600–mutant advanced melanoma.

Tycel Phillips, MD, discusses a phase 1/2 trial combining subcutaneous epcoritamab with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma, as presented at the 63rd ASH Annual Meeting in 2021.

Dr Smith reviews post-hoc data from the OPTIC trial which assessed the safety and efficacy of ponatinib in patients with CP-CML whose disease was resistant to 2 or more TKIs or who have a T3151 mutation.

Expert hematologist/oncologist Joseph Mikhael, MD, shares insight on the phase III GMMG-HD7 trial, which added isatuximab to RVd in the setting of newly diagnosed, transplant-eligible multiple myeloma.

Leon Bernal-Mizrachi, MD, discusses efficacy and safety updates to the US MM-6 study that was presented at the ASH 63rd Annual Meeting in 2021, as well as reasons for premature discontinuation, for patients with newly diagnosed multiple myeloma (NDMM).

Thomas G. Martin, MD, explains the updated results from CARTITUDE-1, a clinical trial that studied ciltacabtagene autoleucal in patients with relapsed/refractory multiple myeloma, that were presented at the ASH 63rd Annual Meeting in 2021.

Anthony Mato, MD, discusses updated efficacy and safety results from the phase 1/2 BRUIN study of the noncovalent BTK inhibitor, pirtobrutinib, in patients with previously treated CLL/SLL that was presented at the American Society of Hematology 2021 Annual Meeting.

Tycel Phillips, MD, discusses EPCORE DLBCL-1, a phase trial that focused on testing epcoritamab against other regiments for patients with relapsed or refractory diffuse large B-cell lymphoma, as presented at the 63rd ASH Annual Meeting in 2021.

Michael L. Wang, MD, discusses the updated results from the Phase 1/2 BRUIN clinical trial, which focused on the use of pirtobrutinib in previously treated mantle cell lymphoma.

Frederick L. Locke, MD, discusses the results from the ZUMA-7 clinical trial that focused on axicabtagene ciloleucel, as presented at the 63rd ASH Annual Meeting in 2021.

Pau Montesinos, MD, PhD, discusses the AGILE phase 3 clinical trial for newly diagnosed patients with acute myeloid leukemia with an IDH1 mutation that was presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition in 2021, from study designs to data results.

Eytan Stein, MD, discusses the AUGMENT-101 trial and menin inhibition in patients with MLL-rearranged and NPM1 mutant acute leukemia, which was presented at the 63rd ASH Annual Meeting in 2021.

Moshe Yair Levy, MD, discusses the safety and efficacy in a phase 2 trial that focused on naratuximab emtansine plus rituximab for the treatment of B-cell lymphomas, as presented at the 63rd ASH Annual Meeting in 2021.

Expert perspectives on the phase II clinical trial assessing IRV triplet therapy in young patients with previously untreated mantle cell lymphoma to help minimize chemotherapy exposure.

Dr Bachelot, MD, PhD, presents updated results from the HER2CLIMB trial of tucatinib plus trastuzumab and capecitabine versus placebo plus trastuzumab and capecitabine in patients with HER2-positive breast cancer with brain metastases.

Matthew Davids, MD, MMsc, provides preliminary information on the MAJIC trial from his ASH 2021 presentation, which will focus on the comparison of venetoclax combined with acalabrutinib and obinutuzumab, respectfully, for the treatment of CLL or SLL.

Matthew Davids, MD, MMsc, presents John F. Seymour, MBBS, FRACP, PhD’s presentation from ASH 2021 on BTKI-related adverse events in the ELEVATE-RR trial that observed acalabrutinib vs ibrutinib for previously treated CLL.

Sara A. Hurvitz, MD, discusses findings from the DESTINY-BREAST03 trial that were presented at the 2021 San Antonio Breast Cancer Symposium that compare trastuzumab deruxtecan (T-DXd) with trastuzumab emtansine (T-DM1) for patients with HER2+ metastatic breast cancer.

Jonathan E. Brammer, MD, reports data presented at the 2021 American Society of Hematology Annual Meeting regarding interim analysis study results from the phase 2 PRIMO trial evaluating the use of duvelisib monotherapy in patients with relapsed/refractory peripheral T-cell lymphoma.

Dr Carrie Lynn Kitko discusses updated results from a phase 1/2 study evaluating the safety, tolerability, and efficacy of axatilimab in pts ≥ 6 years of age with active cGVHD despite ≥ 2 prior lines of systemic therapy.

Afshin Dowlati, MD, discusses data from the following presentation: “Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the Phase 3 CASPIAN study.” (Paz-Ares, ESMO 2021, LBA61)

Alexander Drilon, MD, discusses prior therapy and performance status outcomes for larotrectinib in patients with non-CNS TRK fusion cancer that were presented at the European Society of Medical Oncology 2021 annual meeting.

Alexander Drilon, MD, discusses the efficacy and safety data of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion-positive lung cancer that was presented at the World Cancer Lung Conference 2021 annual meeting.

Virginia Kaklamani, MD, DSc, presents results of the DESTINY-Breast03 clinical trial of trastuzumab deruxtecan compared with trastuzumab emtansine as treatment for patients with HER2-positive metastatic breast cancer.

Ronan Kelly, MD, MBA, discusses data from the presentation “Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen.” (Van Cutsem et al, ESMO 2021, LBA55)

William G. Wierda, MD, discusses data from the phase 1 cohort of lisocabtagene maraleucel combined with ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia that was presented at the 19th International Workshop on CLL (iwCLL) held in September 2021.

Expert Riad Salem, MD, MBA, highlights key data from the phase 3 EPOCH study, which evaluated TheraSphere in patients with mCRC and liver metastases who failed first line chemotherapy.

Andrew J. Armstrong, MD, discusses final overall survival data from the phase 3 randomized, double-blind, placebo-controlled ARCHES study of enzalutamide plus androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer presented at the European Society for Medical Oncology 2021 Congress.

Dr Zhang, MD, discusses cognitive assessment data from patients with metastatic castrate-resistant prostate cancer in the ODENZA trial receiving either darolutamide or enzalutamide that was presented at the European Society for Medical Oncology 2021 Annual Meeting.

A. Timothy Schmidt, MD, discusses data from the subgroup analysis of the IKEMA study of isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma and high-risk cytogenetics that was presented at the American Society of Clinical (ASCO) 2021 Annual Meeting.

Expert oncologist Giuseppe Curigliano, MD, PhD, reflects on the updated results of the HER2CLIMB study evaluating tucatinib against placebo, each in combination with trastuzumab and capecitabine, in patients with pretreated HER2+ metastatic breast cancer.

Hope S. Rugo, MD, FASCO, discusses data presented at the 2021 American Society of Clinical Oncology annual meeting from the phase 3 ASCENT study of patients with metastatic triple-negative breast cancer treated with sacituzumab govitecan.

A. Oliver Sartor, MD, presents data from the American Society of Clinical Oncology 2021 annual meeting from the VISION study of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.

Jennifer R. Brown, MD, PhD presents an interim analysis from the ALPINE study of zanubrutinib vs. ibrutinib in patients with R/R CLL/SLL presented at the 2021 European Hematology Association virtual congress.

Ryan Hickey, MD, presents data from the American Society of Clinical Oncology 2021 Gastrointestinal Cancers Symposium on results of the phase 2 DOSISPHERE-01 trial of personalized vs standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma.

Stephen V. Liu, MD, presents data from the 2021 American Society of Clinical Oncology annual meeting on the updated results from the ARROW trial of pralsetinib in patients with RET fusion-positive non-small cell lung cancer.

Jean-Jacques Kiladjian, MD, PhD, describes updated results presented at the European Hematology Association 2021 Virtual Congress from the phase 3 SIMPLIFY-1 trial of momelotinib vs ruxolitinib in JAK inhibitor–naïve patients with myelofibrosis.

Ruben Mesa, MD, Director of UT Health San Antonio MD Anderson Cancer Center, presents data from the 2021 European Hematology Association Virtual Congress from the SIMPLIFY-1 and SIMPLIFY-2 trials of patients with myelofibrosis who were treated with momelotinib.

Scott T. Tagawa, MD, MS, FACP, reports on data presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting regarding health-related quality of life (HRQoL) and patient-reported outcomes (PROs) at the final analysis of TITAN, a phase 3 study evaluating apalutamide versus placebo in patients with metastatic castration-sensitive prostate cancer (mCSPC) who were receiving androgen deprivation therapy (ADT).

David A. Reardon, MD, presents slides, shown at the 2021 American Society of Clinical Oncology Annual Meeting, from the phase 2 NAVIGATE basket trial and the phase 1/2 SCOUT trial in adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion–positive primary central nervous system (CNS) tumors treated with larotrectinib with or without prior therapy.

Alexander Drilon, MD presents data from the 2021 American Society of Clinical Oncology annual meeting from trials in adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive lung cancer treated with larotrectinib.

Alexander Drilon, MD presents updated results from a pooled analysis of TRK fusion-positive cancers treated with larotrectinib from the 2021 American Society of Clinical Oncology annual meeting.

Neal Shore, MD, presents data on the tolerability of and responses to darolutamide (DARO) as seen in the extended follow-up of the phase 3 ARAMIS trial of DARO treatment in men with high-risk, nonmetastatic, castration-resistant prostate cancer. The results were reported at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

Neal Shore, MD, presents data on treatment preferences from the phase 2 ODENZA trial of darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer. The results were reported at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

Ghassan K. Abou-Alfa, MD, reports on data presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting regarding final results from the ClarIDHy trial. In the phase 3 study, investigators examined ivosidenib vs placebo in patients with previously treated cholangiocarcinoma and an isocitrate dehydrogenase 1 mutation.

David R. Spigel, MD, presents data from the 2021 American Society of Clinical Oncology annual meeting on the updated results from the phase 3 PACIFIC trial of durvalumab treatment after chemotherapy in patients with unresectable stage III non-small cell lung cancer

Douglas W. Blayney, MD, presents data from the 2021 American Society of Clinical Oncology Annual Meeting on the final results from the phase 3 PROTECTIVE-2 trial of Plinabulin and Pegfilgrastim in breast cancer patients treated with high febrile neutropenia risk chemotherapy.

Riad Salem, MD, presents slides supporting global real-world data confirming a significant association between tumor-absorbed dose, objective response between tumor-absorbed dose and overall survival in patients with hepatocellular carcinoma (HCC) treated with yttrium-90 glass microspheres.

Tycel J. Phillips, MD, presents slides from the American Association for Cancer Research (AACR) Virtual Annual Meeting 2021 of results from the phase 3 CHRONOS-3 study of copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (iNHL).

Joshua F. Zeidner, MD, presents data from the 62nd American Society of Hematology (ASH) Annual Meeting on an exploratory analysis of patient-reported outcomes from a randomized phase 2 trial of pevonedistat plus azacitidine vs azacitidine in higher-risk myelodysplastic syndrome (MDS)/chronic myelomonocytic leukemia (CMML) or low-blast acute myeloid leukemia (AML).

Alexander Spira, MD, PhD, FACP, presents slides from the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer (WCLC) from CodeBreak 100, the phase 2 trial of sotorasib in KRASG12C-mutated non–small cell lung cancer.

Kim N. Chi, MD, presents slides from the 2021 ASCO Genitourinary Cancers Symposium for the final results from the phase 3 TITAN study of apalutamide versus placebo in patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy.

Roy S. Herbst, MD, PhD, presents slides from the IASLC 2020 World Conference on Lung Cancer for postoperative chemotherapy use and outcomes from the phase 3 ADAURA trial of osimertinib as adjuvant therapy in patients with resected EGFR mutated NSCLC.

Roy S. Herbst, MD, PhD, presents slides from the IASLC 2020 World Conference on Lung Cancer for patient-reported outcomes from the phase 3 ADAURA trial of osimertinib as adjuvant therapy in patients with resected EGFR mutated NSCLC.